Several other brokerages also recently commented on ACIU. Zacks Investment Research downgraded shares of AC Immune from a buy rating to a hold rating in a report on Tuesday, February 12th. ValuEngine downgraded shares of AC Immune from a hold rating to a sell rating in a report on Monday, March 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. AC Immune has an average rating of Hold and a consensus price target of $11.94.
Shares of ACIU stock opened at $5.25 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.06. The company has a market cap of $340.51 million, a price-to-earnings ratio of -6.40 and a beta of -0.16. AC Immune has a 52 week low of $3.25 and a 52 week high of $17.40.
AC Immune (NASDAQ:ACIU) last announced its earnings results on Wednesday, May 15th. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.36). The company had revenue of $75.28 million for the quarter, compared to analyst estimates of $106.81 million. AC Immune had a return on equity of 12.17% and a net margin of 29.66%. On average, analysts forecast that AC Immune will post 0.69 EPS for the current year.
A number of hedge funds have recently made changes to their positions in ACIU. BVF Inc. IL raised its holdings in AC Immune by 234.3% during the 1st quarter. BVF Inc. IL now owns 7,455,534 shares of the company’s stock worth $37,650,000 after buying an additional 5,225,507 shares during the period. Prosight Management LP acquired a new stake in shares of AC Immune in the first quarter valued at approximately $3,588,000. BlackRock Inc. acquired a new stake in shares of AC Immune in the fourth quarter valued at approximately $6,092,000. FMR LLC raised its holdings in shares of AC Immune by 7.7% in the fourth quarter. FMR LLC now owns 5,612,759 shares of the company’s stock valued at $53,039,000 after purchasing an additional 403,086 shares during the last quarter. Finally, Artisan Partners Limited Partnership acquired a new stake in shares of AC Immune in the first quarter valued at approximately $903,000. Hedge funds and other institutional investors own 26.54% of the company’s stock.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading: How to track put option volume
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.